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The impact of increased serum concentrations of plant sterols on cardiovascular risk is unclear. We conducted a systematic review and meta-
analysis aimed to investigate whether there is an association between serum concentrations of two common plant sterols (sitosterol, cam-
pesterol) and cardiovascular disease (CVD). We systematically searched the databases MEDLINE, EMBASE, and COCHRANE for studies
published between January 1950 and April 2010 that reported either risk ratios (RR) of CVD in relation to serum sterol concentrations
(either absolute or expressed as ratios relative to total cholesterol) or serum sterol concentrations in CVD cases and controls separately.
We conducted two meta-analyses, one based on RR of CVD contrasting the upper vs. the lower third of the sterol distribution, and another
based on standardized mean differences between CVD cases and controls. Summary estimates were derived by ﬁxed and random effects
meta-analysis techniques. We identiﬁed 17 studies using different designs (four case–control, ﬁve nested case–control, three cohort, ﬁve
cross-sectional) involving 11182 participants. Eight studies reported RR of CVD and 15 studies reported serum concentrations in CVD cases
and controls. Funnel plots showed evidence for publication bias indicating small unpublished studies with non-signiﬁcant ﬁndings. Neither of
our meta-analyses suggested any relationship between serum concentrations of sitosterol and campesterol (both absolute concentrations
and ratios to cholesterol) and risk of CVD. Our systematic review and meta-analysis did not reveal any evidence of an association
between serum concentrations of plant sterols and risk of CVD.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Cardiovascular disease (CVD) is the leading cause of death world-
wide.
1 Elevated LDL-cholesterol (LDL-C) concentrations constitute
a major cardiovascular risk factor.
2 There is substantial evidence that
the incidence of CVD can be reduced by lowering LDL-C, either
through diet or through the use of lipid-lowering agents, primarily
statins.
3–6 In this regard, it is relevant that ingestion of supplements
of plant sterols (also called phytosterols) has been known to effect-
ively lower serum concentrations of cholesterol and LDL-C since
the early 1950’s.
7–9 Phytosterols are cholesterol homologues princi-
pally found in nuts, fruits, and seeds, and are present in the diet in
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10,11 In con-
trast to cholesterol, phytosterols are poorly absorbed, resulting in
circulating concentrations of ,1 mg/dL.
12 Their lipid-lowering
effect is mediated by competitive inhibition of cholesterol absorption
and by transcriptional induction of genes implicated in cholesterol
metabolism in both enterocytes and hepatocytes.
13
The cholesterol-lowering properties of phytosterols have there-
fore also been exploited in the preparation of functional foods.
14
However, despite the potential positive impact on cardiovascular
risk due to cholesterol lowering, concerns have been raised that
plant sterols may also exert adverse cardiovascular effects, for
two major reasons
15,16 First, individuals with sitosterolaemia, a
rare autosomal recessive inherited disorder, in which serum phy-
tosterol concentrations are elevated 50–100-fold, may display pre-
mature and severe CVD.
17,18 This disease was ﬁrst described by
Bhattacharyya and Connor
19 and is caused by mutations in the in-
testinal and hepatic ATP-binding cassette transporters G5 and G8
(ABCG5/ABCG8).
20,21 In subjects with sitosterolaemia, choles-
terol and LDL-C concentrations may be normal, but also moder-
ately increased.
17,18 Secondly, some but not all population-based
studies have reported associations between elevated serum con-
centrations of plant sterols and CVD.
22–24
We conducted a systematic review and meta-analysis of epidemio-
logical studies to investigate whether there is an association between
serum concentrations of plant sterols and CVD. We focused on two
commonplantsterols,sitosterolandcampesterol,whichtogethercon-
stitute .90% of the sterols occurring in diet and circulating blood.
11
Methods
Data sources, search strategy, and selection
criteria
We conducted a systematic review of the published literature accord-
ing to the PRISMA statement for the conduct of meta-analyses of epi-
demiological studies.
25 Relevant studies were identiﬁed by searching in
the following data sources: MEDLINE via PUBMED (from 1950 to
April 2010), EMBASE (from 1996 to April 2010), and the COCHRANE
library (from 1988 to April 2010). Search terms including key words
and headings were related to plant sterol exposure (‘phytosterol’,
‘plant sterol’, ‘sitosterol’, or ‘campesterol’) and to CVD (‘atheroscler-
osis’, ‘coronary heart disease’, ‘coronary artery disease’, ‘angiography’,
‘cardiovascular disease’, ‘cardiovascular mortality’, ‘cardiovascular risk’,
‘cardiovascular event’, ‘stenosis’, ‘atherosclerotic plaque’, ‘coronary
calcium’, ‘vascular’, ‘stroke’, ‘myocardial infarction’, ‘peripheral arterial
disease’, or ‘cerebrovascular disease’). Two authors (B.G. and
K.C.D.) conducted independently the literature search, data extraction,
and quality assessment by using a standardized approach. We included
studies with different research designs that reported data on the asso-
ciation between serum concentrations of campesterol/ sitosterol and
CVD. Details of eligibility criteria are shown in Table 1. As few
studies were eligible and as authors employed heterogeneous end-
points related to CVD, we deﬁned a composite of major clinical car-
diovascular events as the primary endpoint for our meta-analysis.
The endpoint includes different deﬁnitions of CVD (shown in Table 1).
Data extraction
For each study identiﬁed, we obtained the original publications and
extracted the following data into a spreadsheet: author, year of publi-
cation, country of origin, research design, major characteristics of the
study population, descriptive statistics of the sterol serum concentra-
tions (if provided for CVD cases and controls separately), or risk
ratios (RR) with respect to CVD according to serum plant sterol con-
centrations (i.e. odds ratios, incidence rate ratios, or hazard ratios), the
statistical method used for analysis, and the covariates adjusted in
multivariate modelling. We applied standardization procedures to syn-
thesize data from studies that used different units of measurements for
sterol concentrations or used different cut-off concentrations for the
calculation of RR (including comparisons of thirds, quarters, ﬁfths,
etc., or continuous increases in risk for a given absolute increase in ex-
posure level). We transformed absolute sterol concentrations into mg/
dl and ratios to total cholesterol into mg/mg. For studies that reported
RR, we transformed the RR to compare individuals in the top third vs.
those in the bottom third of the sterol distribution. Statistical details of
the standardization approach for RR have been published elsewhere.
26
If authors reported several estimates of RR derived from multiple
models using different sets of adjusting variables, we considered the es-
timate adjusted for all potential confounding variables (that have been
collected in the particular study) as the gold standard estimate. We
assessed the set of potential confounding variables by a pre-deﬁned
conceptual model (Figure 1). The model presumes that phytosterol
serum concentrations act at the same causal level as cholesterol con-
centrations, both being strongly affected by individual intake and ab-
sorption capacity. Thus, consistent risk estimates for sterols should
be adjusted for cholesterol concentrations (especially LDL-C) to
avoid any bias due to a common mechanism that might affect intestinal
absorption of both cholesterol and non-cholesterol sterols, such as
genetic factors.
27
For studies that reported phytosterols in CVD cases and controls
separately, we calculated standardized mean differences (SMD) and
Table 1 Eligibility criteria
Inclusion criteria
Study design: cohort study, parallel- or cross-over trial, cross-sectional
study, case–control study, nested case–control study
Provided data on one of the following deﬁnitions of CVD:
Non-fatal coronary heart disease: non-fatal myocardial infarction,
coronary artery calcium determined by electron beam computer
tomography, and carotid stenosis ≥50% veriﬁed by Doppler
ultrasound
Non-fatal cerebrovascular events: non-fatal stroke, transient ischaemic
attack, prolonged reversible ischaemic neurological deﬁcit
Death due to CVD: death due to coronary heart disease,
cerebrovascular disease, or peripheral vascular disease
Reported on exposure: serum concentrations of sitosterol/
campesterol (absolute values or ratios to total cholesterol)
Reported association measures (hazard ratio, odds ratios, or incidence
rate ratios) between exposure and CVD or descriptive statistics of
exposure serum concentrations in CVD cases and controls
separately
Publication in English, French, German, Spanish, Portuguese
Exclusion criteria
No original paper published in any periodical indexed in one of our
search databases
Used a history based deﬁnition of CVD such as personal and/or family
history of CVD
Used endpoints which were not unequivocally related to CVD such as
aortic valve stenosis, composition of the atheromatous plaque, or
carotid artery compliance
Plant sterols and cardiovascular disease 445standard errors. Equally, we conducted separate analyses to explore
the relationships of absolute phytosterol concentrations and their
ratios to cholesterol with the incidence of CVD.
Statistical analysis
We examined potential publication bias using Begg’s Funnel plots and
Egger’s test. We conducted two different meta-analyses, one based on
the RR (MA 1) and another based on the SMD between CVD cases
and controls (MA 2). For both analyses, we calculated pooled
summary estimates by using ﬁxed effects (the Mantel–Haenszel
method)
28 and random effects (the DerSimonian and Laird model)
29
meta-analysis techniques. As we assumed unexplained heterogeneity
among studies due to heterogeneous study designs and to different
strategies for adjustment of confounding variables, we considered
the random effects estimate as the preferable approach. To further
explore heterogeneity among studies, we calculated I
2 statistics and
used Forest plots visualizing study-speciﬁc estimates and the pooled
ﬁxed and random effects estimators. In addition to the core analysis
using the ‘best adjusted estimate’ (i.e. the estimate adjusted for all avail-
able potential confounding variables), we conducted sensitivity
Figure 1 Conceptual model: plant sterols and cardiovascular disease.
Figure 2 Identiﬁcation process for eligible studies.
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appropriate adjustment. Further, if sufﬁcient studies were available, as
it was the case for MA 2, we additionally conducted subgroup analyses
by study design (results are shown in the Forest plots). Statistical hy-
pothesis testing was conducted two sided with a P-value of 0.05 to
be considered signiﬁcant. All statistical analyses were conducted
using the statistical software package STATA (STATA Corporation,
College Station, TX, USA).
Role of the funding source
The funding source had no role in data analysis, data interpretation, or
in the writing of the manuscript. The ﬁrst author (B.G.) had full access
to all data used in the study. All authors had responsibility for the de-
cision to submit the article for publication.
Results
Literature search and selected studies
The literature search yielded 954 abstracts from three different
databases, of which 59 publications were selected to be reviewed
in full text (Figure 2). Of these, we excluded 33 studies as phytos-
terol concentrations were not explicitly reported; a further nine
studies were equally excluded as study endpoints or deﬁnitions
of CVD did not meet our inclusion criteria. We excluded studies
that used ‘family history of CVD (or CHD)’ as the study end-
point,
30–32 together with studies that employed endpoints which
were not unequivocally related to CVD such as aortic valve sten-
osis,
33 composition of the atheromatous plaque,
34,35 and carotid
artery compliance.
36 Furthermore, we excluded a study that did
not report any association measures that we could extract for
the proposed data synthesis (i.e. RR or SMD), such as correlation
coefﬁcients between PS concentrations with a severity score of
coronary artery disease,
37 and a study that was published in ab-
stract form only.
38
Finally, we selected 17 studies (4 case–control, 3 cohort, 5
cross-sectional and 5 nested case–control studies) for the
present meta-analysis, including a total of 11 182 participants
22–
24,39–52 (Supplementary material online, Table A1). Eight studies
reported relative risks based on phytosterol exposure in relation
to CVD endpoints; 15 studies reported summary statistics of phy-
tosterol concentrations in CVD cases and controls separately.
Published studies involved sample sizes that ranged from 40 to
2440 participants with the mean age ranging from 48 to 78
years. Funnel plots (data not shown) indicated the presence of
publication bias with a lack of publication of small studies with non-
signiﬁcant ﬁndings. Moreover, we found that publication bias was
higher in studies which provided mean differences in phytosterol
concentrations between CVD cases and controls (MA 2), when
compared with those which analysed RR for CVD outcomes
(MA 1).
Meta-analysis
Table 2 shows a summary of the two meta-analyses (MA 1: based
on RR, and MA 2: based on SMD) conducted for the two phytos-
terols for both absolute values and ratios to cholesterol. Figures 3–
6 show Forest plots visualizing the study-speciﬁc estimates and the
pooled summary estimates (both ﬁxed and random effects).
For campesterol, the meta-analysis based on RR (Figure 3)
showed homogenous estimates among studies and a non-
signiﬁcant pooled summary estimate for both absolute concentra-
tions (Figure 3A:R R¼ 1.02, P ¼ 0.675) and ratios to total choles-
terol (Figure 3B:R R ¼ 1.19, P ¼ 0.150). The meta-analysis using
SMDs between CVD cases and controls (Figure 4A) revealed het-
erogeneous estimates among studies (I
2 ¼ 79%, P , 0.001), includ-
ing three studies
22,23,41 with positive associations. Subgroup
analysis by study design partly explained these inconsistent
results. Case–control studies and nested case–control studies
appeared to show a tendency towards increased campesterol con-
centrations in CVD cases compared with controls. However, the
pooled meta-analysis estimate was non-signiﬁcant (SMD ¼ 0.09,
P ¼ 0.400). The plot for campesterol to cholesterol ratios
(Figure 4B) also revealed a heterogeneous pattern of estimates
(I
2 ¼ 83%, P , 0.001). We observed studies with either positive
or negative associations that scattered around the pooled
summary estimate, which itself was close to zero and non-
signiﬁcant (SMD ¼ 0.02, P ¼ 0.770). Again, subgroup analysis
could only, to some extent, explain the observed heterogeneity.
In the case of sitosterol, only three studies reported RR
(Figure 5A) with respect to CVD based on absolute serum phytos-
terol concentrations. The results of these studies were heteroge-
neous (I
2 ¼ 84%, P ¼ 0.002), including one study which reported
a signiﬁcant relationship.
22 The summary estimate was non-
signiﬁcant (RR ¼ 1.06, P ¼ 0.644), indicating the absence of an
effect. The plot for sitosterol to cholesterol ratios (Figure 5B)
also demonstrated a heterogeneous pattern (I
2 ¼ 55%, P ¼
0.030). Most studies showed non-signiﬁcant results, the one by
Assmann et al.
22 being the only estimate which indicated a positive
association. Again, the pooled estimate was not signiﬁcant (RR ¼
0.94, P ¼ 0.730).
Similarly, the meta-analysis of SMDs of sitosterol in CVD cases
and controls (Figure 6A) showed substantial heterogeneity (I
2 ¼
82%, P , 0.001) and a non-signiﬁcant summary estimate (SMD ¼
0.09, P ¼ 0.400). We identiﬁed studies which reported either posi-
tive or negative associations of phytosterol exposure with CVD.
Stratiﬁed analysis revealed that only part of this heterogeneity
could be explained by study design. The plot of the SMDs for sitos-
terol to cholesterol ratios (Figure 6B) also showed substantial het-
erogeneity (I
2 ¼ 78%, P , 0.001) and a non-signiﬁcant pooled
estimate (SMD ¼ 0.01, P ¼ 0.837). Again, stratiﬁed analysis by
study design was able to explain some of this heterogeneity and
indicated a tendency towards positive associations between phy-
tosterol exposure and CVD in case-control studies. Of note, sen-
sitivity analyses conducted for the meta-analysis based on the RR
(MA 1) failed to reveal any major impact of excluding data from
studies with non-appropriate adjustment for covariates.
Discussion
This systematic review and meta-analysis based on the ﬁndings
from 17 studies involving 11 182 subjects did not yield any evi-
dence of an association between serum concentrations of plant
sterols and elevated risk of CVD. This is true for both campesterol
and sitosterol, for absolute concentrations and their ratios to total
cholesterol, and regardless of whether we considered RR for CVD
Plant sterols and cardiovascular disease 447based on tertiles of plant sterol concentrations or mean concen-
trations in CVD cases compared with controls.
Interestingly, the studies identiﬁed by our systematic literature
review reported highly inconsistent ﬁndings. Some studies sug-
gested that elevated circulating concentrations of plant sterol
concentrations (or their ratios to cholesterol) might increase the
risk of CVD, namely the PROspective CArdiovascular Mu ¨nster
study,
22 the Framingham Offspring Study,
24 the Drugs and Evi-
dence BAsed medicine in The Elderly study,
49 a cohort of subjects
with aortic stenosis,
50 the Pittsburgh Epidemiology of Diabetes
Complications Study,
45 and two Finish studies in postmenopausal
women.
23,41 A similar modest trend was also seen in participants
of the LUdwigshafen RIsk and Cardiovascular health study in multi-
variate analysis adjusted for potential confounding variables.
46,47 In
contrast, other studies reported negative associations of plant
sterols with cardiovascular risk, namely the Longitudinal Aging
Study Amsterdam,
39 the European Prospective Investigation of
Cancer Norfolk and Spain cohorts,
39,43 and the COronary Risk
factors for Atherosclerosis in women study.
52 Finally, three
studies indicated that plant sterol concentrations are not at all
related to CVD, i.e. the Dallas Heart Study,
51 the PROspective
Study of Pravastatin in the Elderly at Risk trial,
42 and the Helsinki
Businessmen Study.
48
A likely explanation for the inconsistent ﬁndings is that authors
used different study designs and adjustments for potential con-
founding variables. Bias is likely if investigators did not appropriate-
ly adjust for all potential confounding variables. Most importantly,
we have to consider bias due to confounding by lipoprotein con-
centrations (i.e. LDL-C concentrations, an established important
risk factor for CVD). According to our conceptual model, there
are common factors affecting intestinal absorption of both choles-
terol and plant sterols creating a correlation between sterol and
lipoprotein concentrations (Figure 1).
53 Indeed, cholesterol
uptake in the gut resulting in increased total and LDL cholesterol
serum concentrations has per se been suggested to represent an
independent cardiovascular risk factor and might therefore
account for a potential association of elevated plant sterol concen-
trations in serum with CVD.
46,47,54 Furthermore, absorption in the
gut is strongly inﬂuenced not only by genetic factors,
27 but also by
age, gender, diet, metabolic background, and medication
(Figure 1).
46,47,55–63 For example, the metabolic syndrome, insulin
resistance, and type 2 diabetes are associated with low-circulating
...............................................................................................................................................................................
Table 2 Summary of the random effects meta-analysis
Exposure n RR
a 95% CI P-value
b n SMD
c 95% CI P-value
b
Campesterol
Absolute 2 1.02 0.94–1.09 0.675 7 0.09 20.10–0.28 0.368
Ratio to Chol 6 1.19 0.94–1.50 0.150 15 0.02 20.10–0.14 0.770
Sitosterol
Absolute 3 1.06 0.84–1.34 0.644 6 0.09 20.12–0.29 0.400
Ratio to Chol 8 0.94 0.68–1.31 0.730 14 0.01 20.09–0.12 0.837
aRandom effects estimates of the risk ratio comparing the upper vs. the lower third of the distribution with the endpoint ‘all CVD events pooled’ (MA 1).
bSigniﬁcance level of testing the hypothesis of absence of effect (i.e. RR ¼ 1 and SMD ¼ 0, respectively).
cStandardized mean difference between CVD cases and controls (MA 2).
Figure 3 Serum levels of campesterol and risk of cardiovascular disease (A: absolute concentrations, B: ratios to total cholesterol). D + L:
DerSimonian & Laird random effects estimate; I-V: inverse variance ﬁxed effects estimate; diamonds: point estimate and 95% conﬁdence inter-
val; boxes: size proportional to study weight for random effects approach; black line: reference line indicating the absence of effect; blue line:
point estimate of random effects approach.
B. Genser et al. 448Figure 4 Serum levels of campesterol in CVD cases and controls (A: absolute concentrations, B: ratios to total cholesterol). D + L: DerSi-
monian & Laird random effects estimate; I-V: inverse variance ﬁxed effects estimate; diamonds: point estimate and 95% conﬁdence interval;
boxes: size proportional to study weight for random effects approach; black line: reference line indicating absence of effect; blue line: point
estimate of random effects approach.
Figure 5 Serum levels of sitosterol and risk of cardiovascular disease (A: absolute concentrations, B: ratios to total cholesterol). D + L: Der-
Simonian & Laird random effects estimate; I-V: inverse variance ﬁxed effects estimate; diamonds: point estimate and 95% conﬁdence interval;
boxes: size proportional to study weight for random effects approach; black line: reference line indicating absence of effect; blue line: point
estimate of random effects approach.
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55,58 In contrast, poor nutritional status, an
index of frailty in elderly people, is correlated with high plant sterol
concentrations. The associations of the metabolic syndrome/type 2
diabetes
64,65 and frailty
66 with increased cardiovascular risk may
thus feign both the inverse and positive relationships of plant
sterols with CVD, respectively. Further, confounding due to nutri-
tional factors may occur. Elevated serum plant sterol concentra-
tions reﬂect enrichment of plant-based food in the diet.
12,39
Diets rich in fruits, seeds, vegetable protein, and polyunsaturated
fatty acids, such as the Mediterranean diet, are considered
healthy, may reduce cardiovascular risk, and thereby underlie the
association of subnormal plant sterol concentrations with CVD.
In the meta-analysis based on the RR, we tried to minimize po-
tential bias due to uncontrolled confounders by selecting the
best-adjusted estimate according to our conceptual model. Inter-
estingly, there was still substantial heterogeneity among studies;
an explanation might be that authors used different statistical
approaches and adjusted for different potential confounding vari-
ables. Of note, in our meta-analysis of mean differences of sterol
concentrations between CVD cases and controls, heterogeneity
among studies was even higher. This ﬁnding is not surprising
since most investigators presented only crude-unadjusted statistics
of the exposure distributions, so that our calculated mean differ-
ences do not provide unbiased estimates of the effect of sterols
on CVD. For example, if there are any CVD risk factors with cor-
relations to sterols (which is likely, e.g. lipoproteins) altered sterol
concentrations in CVD cases might only be a proxy for other CVD
risk factors.
Plant sterols have been ascribed atherogenic effects, mainly
because atherosclerosis has been encountered in patients with
phytosterolaemia which is accompanied by extremely high concen-
trations of plant sterols. Equally, however, serum phytosterol con-
centrations have been demonstrated to correlate with
atherosclerotic plaque burden in individuals not affected by this
Figure 6 Serum levels of sitosterol in CVD cases and controls (A: absolute concentrations, B: ratios to total cholesterol). D + L: DerSimo-
nian & Laird random effects estimate; I-V: inverse variance ﬁxed effects estimate; diamonds: point estimate and 95% conﬁdence interval; boxes:
size proportional to study weight for random effects approach; black line: reference line indicating absence of effect; blue line: point estimate of
random effects approach.
................................................................................
Table 3 Average serum concentrations of plant
sterols in the ﬁrst and third tertiles of their distributions
in the studies included in the meta-analysis
Midpoint
a
(ﬁrst tertile)
Midpoint
a
(third
tertile)
Factor
b
(third /ﬁrst
tertile)
Sitosterol (mg/dL) 0.13 0.38 3.1
Sitosterol:Chol 0.44 1.69 3.6
Campesterol (mg/
dL)
0.17 0.57 3.7
Campesterol:Chol 0.94 2.49 3.4
aAverage midpoint of tertiles across studies.
bAverage ratio (midpoint of third tertile/ midpoint of ﬁrst tertile) across studies.
B. Genser et al. 450disease.
34,35 Our meta-analysis, however, argues against an associ-
ation between moderately elevated concentrations of plant sterols
and CVD.
In the studies recruited for this meta-analysis, plant sterol con-
centrations vary at least by threefold, as indicated by a comparison
of the midpoints of the lower and upper tertiles of sitosterol and
campesterol distributions (Table 3). This range should be wide
enough to detect relevant changes of cardiovascular risk due to
moderate and commonly occurring variations in phytosterol levels.
There is evidence that the tissue content of plant sterols relates
to their concentration in the plasma.
67 Tissue levels were higher in
individuals consuming sterol-enriched foods than in individuals who
did not. Tissue deposition of plant sterols is most likely a passive
process driven by the respective plasma concentration. A similar
correlation may also exist between plasma and tissue cholesterol,
but this was unfortunately not examined in that study. A mere cor-
relation between minute amounts of plant sterols in the plasma
and in tissue would, in addition, not prove a speciﬁc causal role
of plant sterols in atherosclerosis, at least as long as it has not
been shown that plant sterols would biologically be much more
active than cholesterol on a equimolar basis.
Our systematic review and meta-analysis have several limita-
tions. First, it was based only on few observational studies and is
therefore prone to bias due to uncontrolled confounding. In par-
ticular, our inability to properly adjust for all potential confounders
might confound the association estimates. We have implemented
an analytical strategy to minimize this potential bias due to uncon-
trolled confounding. First, we deﬁned a conceptual model specify-
ing the set of potential confounding variables. Secondly, we
extracted from each study the best-adjusted estimates according
to this model. Unfortunately, not all authors provided fully adjusted
estimates so that we must assume some residual bias. Thus, we
also considered the possibility of a sensitivity analysis, i.e. repeating
the analysis by excluding all studies without appropriate adjustment
for potential confounding variables. However, the number of
studies was too small to effectively implement this approach.
Further, the second meta-analysis based on SMD between CVD
cases and controls (MA 2) is likely to be biased since most
studies only provided crude-unadjusted statistics of the sterol dis-
tributions. An analysis based on multivariate predicted means of
sterol concentrations adjusted for potential confounding variables,
such as provided in the LUdwigshafen RIsk and Cardiovascular
Health study,
44 would be a preferable analytical approach to
obtain further evidence for any causal relationship between
sterol serum concentrations and CVD. Secondly, since only a
few studies were eligible, we pooled results from studies involving
different designs and dissimilar deﬁnitions of CVD.
Thus, as a direct consequence, it was necessary to deﬁne a com-
posite cardiovascular endpoint, including not only coronary but
also cerebrovascular and peripheral vascular events which might
increase noise and reduce the power of our meta-analysis.
Finally, we also had to consider publication bias as indicated by a
lack of small studies published resulting in a slight overestimation
of the true effect of plant sterols on CVD risk.
Even though our meta-analysis has several limitations, it repre-
sents the ﬁrst systematic attempt to critically appraise the evidence
surrounding the relationship of plant sterols and their ratios to
cholesterol with CVD. We are convinced that even by pooling het-
erogeneous studies, one can substantially contribute to new
insights if the basic assumption holds that there was no systematic
methodological bias present. Study heterogeneity might increase
noise and reduce power, but, if none of the investigators tried to
force/mask the true effect by systematically selecting a particular
research design, statistical approach, and/or strategy to adjust for
potential confounding variables, then a meta-analysis should be
able to obtain consistent summary estimates. However, based on
the present meta-analysis of observational studies, evidence is
still limited and further research will be necessary to assess
whether plant sterols are causally involved in atherogenesis. The
next level of evidence might be the conduct of an individual
patient data meta-analysis retrieving the original data of the
studies considered here. A centralized reanalysis of the data in
each study in a consistent way would afford a decrease in hetero-
geneity and bias in summary estimates by enhancing correction for
potential confounding variables.
In conclusion, our systematic review and meta-analysis do not
provide any evidence that there is an association between moder-
ate ﬂuctuations of serum concentrations of plant sterols and CVD
risk. However, our meta-analysis does not address the vascular
effects or safety of long-term consumption of plant sterol-enriched
foods.
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